Home
GSC Advanced Research and Reviews
Peer-reviewed | Multidisciplinary Journal | Impact factor 8.3 | ISSN: 2582-4597 | Crossref DOI

Main navigation

  • Home
    • Journal Information
    • Editorial Board Members
    • Reviewer Panel
    • Abstracting and Indexing
    • Journal Policies
    • Our CrossMark Policy
    • Publication Ethics
    • Issue in Progress
    • Current Issue
    • Past Issues
    • Instructions for Authors
    • Article processing fee
    • Track Manuscript Status
    • Get Publication Certificate
    • Join Editorial Board
    • Join Reviewer Panel
  • Contact us
  • Downloads

The role of the gut micro biota in kidney disease

Breadcrumb

  • Home
  • The Role of The Gut Micro Biota In Kidney Disease
  • The role of the gut micro biota in kidney disease

José Lucas Daza López 1, *, Yaroslad De La Cruz Prieto 1, Gerardo Fabio Gutierrez Aviles 1, Luis Carlos Puello Gonzalez 1 and Nestor Pablo Guarnizo Bustamante 2

1 Internal Medicine-Nephrology, Medicine Department/University of Buenos Aires, Argentina.
2 General Medicine, Medicine Department/University of Tolima, Colombia.
 
Research Article
GSC Advanced Research and Reviews, 2023, 14(03), 292–299.
Article DOI: 10.30574/gscarr.2023.14.3.0106
DOI url: https://doi.org/10.30574/gscarr.2023.14.3.0106
Received on 21 February 2023; revised on 28 March 2023; accepted on 31 March 2023
 
There is increasing evidence of the influence of the gut microbiota on kidney diseases and precursors such as hypertension, diabetes, cardiovascular diseases and its complications, such as stroke, heart failure, and myocardial infarction. This is no surprising considering that the most common risk factor for hypertension, such as age, sex medication, and diet, can also impact the gut microbiota.
For example, sodium and fermentable fiber have been studied in relation to both hypertension and the gut microbe Inflammation and fibrosis are the important pathophysiologic processes in diabetic kidney disease (DKD), which is induced by epigenetics, especially histone posttranslational modification (HPTMs). Have been indicated to play different roles in the repair of DNA damage.
Recent reports highlighted that butyrate, one of the short-chain fatty acids (SCFAs) primarily originated from the fermentation of dietary fiber in the gut, attenuates inflammation and fibrosis in the prevention and treatment of DKD, however the molecular mechanisms are still unclear.
Histone lysine butyrylation (Kbu), a novel histone modification marker induced by butyrate, has been found to be involved in the regulation of pathophysiological processes. To reveal the mechanisms of butyrate-induced histone (Kbu), in the prevention and treatment of DKD, both DKD models in vivo and in vitro were treated with sodium butyrate (NaB). The results confirmed that exogenous NaB improved the disorder of glucose and lipid metabolism, prevented proteinuria and renal failure, and inhibited renal inflammation and fibrosis
New treatment options in the form of prebiotics (dietary fiber), probiotics (lactobacillus spp) and postbiotics (the short-chain fatty acids acetate, propionate, and butyrate) have all been demonstrated to be beneficial in the kidney disease.
We should include short-chain fatty acids such as butyric acid in our patients with kidney disease regardless of the etiology to maintain the intestinal microbiota and avoid dysbiosis that causes inflammation, proteinuria, endothelial dysfunction.
 
DKD (diabetic kidney disease); HPTMs (histone posttranslational modification); SCFAs (short-chain fatty acids); KBU (histone lysine butyrylation) NaB(sodium butyrate); Histone deacetylases (HDACs); Proliferator-activated receptors (PPARs); Glucagon-like peptide 1 (GLP1); CKD ( chronic kidney disease); AKI ( acute kidney injury)
 
https://gscarr.gsconlinepress.com/sites/default/files/fulltext_pdf/GSCARR-2023-…

Preview Article PDF

José Lucas Daza López, Yaroslad De La Cruz Prieto, Gerardo Fabio Gutierrez Aviles, Luis Carlos Puello Gonzalez and Nestor Pablo Guarnizo Bustamante. The role of the gut micro biota in kidney disease. GSC Advanced Research and Reviews, 2023, 14(3), 292-299. Article DOI: https://doi.org/10.30574/gscarr.2023.14.3.0106

Copyright © Author(s). All rights reserved. This article is published under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as appropriate credit is given to the original author(s) and source, a link to the license is provided, and any changes made are indicated.


All statements, opinions, and data contained in this publication are solely those of the individual author(s) and contributor(s). The journal, editors, reviewers, and publisher disclaim any responsibility or liability for the content, including accuracy, completeness, or any consequences arising from its use.

Get Certificates

Get Publication Certificate

Download LoA

Check Corssref DOI details

Issue details

Issue Cover Page

Editorial Board

Table of content

Copyright © 2026 GSC Advanced Research and Reviews - All rights reserved

Developed & Designed by VS Infosolution